The US food and drug administration’s approval of adjuvant sunitinib for renal cell cancer: A case of regulatory capture?

Bishal Gyawali*, Daniel A. Goldstein

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)623-624
Number of pages2
JournalJAMA Oncology
Issue number5
StatePublished - May 2018
Externally publishedYes

Cite this